Ziltivekimab for heart attack patients with artery plaque
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a recent heart attack and had a stent placed to open a blocked artery.
- You are 18 years old or older.
- You have at least 2 main heart arteries that can be seen with special imaging after the stent procedure.
- You are not able to become pregnant (women who could become pregnant are excluded).
- You do not have severe kidney or liver disease, active infections, or a history of cancer in the last 5 years (except for certain minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ziltivekimab to see if it helps people who have recently had a heart attack. The drug is given as an injection and compared to a placebo (a shot with no active medicine).
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.
This trial tests if meplazumab can help people with chronic coronary syndrome who have stable angina. It focuses on patients with certain fatty deposits around their heart arteries that show up on a special CT scan.
This trial tests if giving a PCSK9 inhibitor (a strong cholesterol-lowering medicine) before a procedure to open blocked heart arteries can help patients who are having a heart attack. It may reduce damage and improve recovery.
This trial is testing a new way to quickly measure the level of a blood thinner (tirofiban) in the blood of people having a heart attack. It aims to make sure the dose is right and safe for each patient.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.